News | May 27, 2023
Labindia partners with Hamilton Laboratory to launch ‘Labindia Hamilton’
Product deliveries scheduled in Q3 of 2023
Product deliveries scheduled in Q3 of 2023
For Q4 ended FY23, company reported net profit of Rs. 12.56 crore as against net profit of Rs. 11.02 crore in the corresponding period last year
The company has reported total income of Rs. 3276.35 crores during the period ended March 31, 2023
The company has reported total income of Rs. 880.59 crores during the period ended March 31, 2023
Continues to Expand its Presence in South India
The drug discovery of mRNA-targeted small molecules is rapidly gaining attention due to the current difficulty of developing drugs against conventional protein targets
The Global Medical Countermeasures Platform will provide equal access safe, high-quality, cost-effective medical countermeasures to the world
The company has reported total income of Rs. 2188.08 crores during the period ended March 31, 2023
Operating EBITDA increased by 21% to INR 181 crores in Q4 FY23
Ensures efficient testing of FeNO as it is a simple tool for the diagnosis, screening & monitoring of Asthma patients
Subscribe To Our Newsletter & Stay Updated
